Search - tctmd.com

Displaying 61 - 80 of 298

Sort: Relevancy | Date

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

L.A. McKeown

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

AHA Updates Advice for Resuscitation, CV Care After Overdose or Poisons

L.A. McKeown

September 20, 2023

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Todd Neale

September 19, 2023

News Daily News

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

Todd Neale

September 13, 2023

News Daily News

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Michael O'Riordan

July 28, 2023

News Daily News

CVD Risk Reduction With Exercise Also Seen in ‘Weekend Warriors’

Michael O'Riordan

July 24, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

AHA Scientific Statement Addresses Health Disparities in PAD

L.A. McKeown

June 23, 2023

News Daily News

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Michael O'Riordan

March 01, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

Advertisement

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 2023 News Roundup

October 2023 News Roundup

AHA Updates Advice for Resuscitation, CV Care After Overdose or Poisons

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

CVD Risk Reduction With Exercise Also Seen in ‘Weekend Warriors’

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

LDL Control Remains Poor in CAD Patients: NHANES

AHA Scientific Statement Addresses Health Disparities in PAD

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content